myelodysplastic syndromes (MDS) is a $3.5b market and Syntara only need to contribute 700k, more importantly it go straight into Phase 2 later this year.
This is substantially more commercialized focus and less time consuming than the previous myelofibrosis trails.
Not sure how long it'll take before the market realize this.
- Forums
- ASX - By Stock
- SNT
- Ann: SNT to Trial New Cancer Indication Following MRFF Grant
Ann: SNT to Trial New Cancer Indication Following MRFF Grant, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.3¢ |
Change
-0.001(2.27%) |
Mkt cap ! $59.04M |
Open | High | Low | Value | Volume |
4.4¢ | 4.4¢ | 4.2¢ | $39.11K | 895.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 752779 | 4.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.4¢ | 200000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 752779 | 0.043 |
1 | 590 | 0.042 |
3 | 1060000 | 0.041 |
8 | 1482500 | 0.040 |
1 | 200000 | 0.039 |
Price($) | Vol. | No. |
---|---|---|
0.044 | 200000 | 1 |
0.045 | 591528 | 2 |
0.046 | 142712 | 2 |
0.049 | 68444 | 2 |
0.050 | 20000 | 1 |
Last trade - 15.58pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
SNT (ASX) Chart |